Abstracts

2022-RA-1591-ESGO MAJOR DETERMINANTS OF SURVIVAL IN RECURRENT ENDOMETRIAL CANCER: THE ROLE OF SECONDARY CYTOREDUCTIVE SURGERY AND RELAPSE PATTERN. A MULTICENTER STUDY

1Virginia Vargiu, 2Andrea Rosati, 2Vito Andrea Capozzi, 3Alessandro Gioi, 4Stefano Restano, 5Aniello Foresta, 6Roberto Beretta, 7Giovanni Scambia, 8Francesco Cosentino, 9Francesco Fanfani, 10Department of Oncology, Gemelli Molise SpA, Campobasso, Italy; 11Department of Woman and Child Health and Public Health, Fondazione Politechico Universitario A. Gemelli IRCCS, Rome, Italy; 12Department of Medicine and Surgery, University of Parma, Parma, Italy; 13Department of Obstetrics, Gynecology, and Pediatrics, Udine University Hospital, DAME, Udine, Italy; 14Università Cattolica del Sacro Cuore, Rome, Italy; 15Department of Medicine and Health Sciences ‘Vincenzo Tiberio’, Università degli studi del Molise, Campobasso, Italy

Introduction/Background Despite advances in endometrial cancer treatments and knowledge, survival for recurring cancers remains poor. In this study, we evaluated the impact of clinical-histological-radiological variables of patients with endometrial cancer recurrence (ECR) on overall-survival (OS), and specifically, we evaluated the impact of secondary-cytoreductive-surgery (SCS) with the achievement of complete gross resection (CGR) on different types of relapses.

Methodology Multicenter-retrospective analysis of patients with ECR.

Results Three-hundred-thirty-one patients were retrieved. At Cox-regression multivariate analysis, age ≥75 yr (HR: 2.056, p=0.003), advanced prognostic risk-group at initial diagnosis (HR: 3.240, p=0.007) and the presence of multiple site relapses (HR: 1.589, p=0.045) resulted to be statistically significant factors for reduced OS, while SCS and the disease-free survival (time from diagnosis to 1 relapse) were predictors of improved OS (respectively HR: 0.161, p<0.001, HR: 0.972, p<0.001) (Figure-1). Survival analysis using the Kaplan-Meier method showed that patients with single-site relapse had an improved OS than patients with multiple-site relapses (log-rank p<0.001) (Figure-1). Further stratifying the population on the surgery performed (SCS with CGR vs SCS with residual tumor (RT)> 0 or other secondary treatment), the Kaplan-Meier curves showed that achieving CGR conferred a statistically significant OS benefit for patients with single site metastases (p=0.044) and a trend towards better survival for patients with multiple site metastases (p=0.090) (figure 1).

Conclusion SCS confirmed to be a statistically independent relevant factor for better OS along with DFS in ECR, while age ≥75 years, the advanced prognostic risk group and the presence of multiple site relapses were significant factors for decreased OS. In addition, the achievement of CGR conferred a statistically significant survival advantage on patients with single-site recurrence compared to patients not operated or operated with RT>0, while a trend toward better survival could be identified in patients with multiple-site relapses when completely gross resected.

2022-RA-1593-ESGO ISOLATED PARA-AORTIC LYMPH NODE METASTASES IN HIGH RISK ENDOMETRIAL CANCER

1Maria Laseca, 2Octavio Arencibia, 3Daniel González, 4Andrés Rave, 2Beatriz Navarro, 3Avinash Ramchandani, 4Alicia Martin, 1Hospital Universitario Materno Infantil de Canarias, Las Palmas de Gran Canaria, Spain; 2Oncology, Hospital Universitario Insular de Canarias, Las Palmas de Gran Canaria, Spain

Introduction/Background Direct metastases to the para-aortic lymph nodes in endometrial cancer are extremely rare. A direct route of lymphatic propagation from the uterus to the para-aortic nodes through the infundibulopelvic ligament has been suggested. The objective of this study was to determine the characteristics and 5 years overall survival of isolated para-aortic lymphatic metastases in high-risk endometrial cancer.

Methodology Retrospective study of patients with high-risk endometrial cancer was performed in a reference center in gynecological oncology. All patients underwent surgery including complete lymph node staging by pelvic and para-aortic lymphadenectomy. Patients were divided into three groups based on the patterns of lymphatic metastases: isolated para-aortic lymphatic metastases, isolated pelvic lymphatic metastases, and dual lymphatic metastases (pelvic and para-aortic metastases). Clinicopathological characteristics and 5-year survival were compared between the three groups.

Results 147 women diagnosed with high-risk endometrial cancer underwent surgery, performing pelvic and para-aortic lymphadenectomy during surgery. The mean age of the patients was 61.62 years. The most common histological type was endometrioid adenocarcinoma (37.4%), followed by serous carcinoma (31.3%). Regarding the histological grade, 77.6% was G3. The most frequent FIGO stage was IA (38.8%). Regarding lymph node dissemination, the proportion of patients with isolated para-aortic lymphatic metastases was 4.76% (n=8), isolated pelvic metastases 17.69% (n=26) and dual metastases (pelvic and para-aortic) 7.48% (n=11). Patients with isolated pelvic lymphatic metastases and isolated para-aortic lymphatic metastases shared similar histologic features. The 5-year overall survival rate in the cohort of patients with isolated para-aortic nodes was 62.5% and 61.5% in the cohort of patients with isolated pelvic nodes. Overall survival in the cohort of patients with metastases duals was 36.4%.

Conclusion Patients with high-risk endometrial cancers with isolated lymphatic and para-aortic metastases and isolated pelvic metastases share similar clinical pathological features and prognoses.